• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA orders label changes for ProHeart 6

November 1, 2003
Jennifer Fiala

Overland Park, Kan.-The U.S. Food and Drug Administration (FDA) has ordered label changes for ProHeart 6 (moxidectin), a six-month injectable heartworm preventive.

Overland Park, Kan.-The U.S. Food and Drug Administration (FDA) has ordered label changes for ProHeart 6 (moxidectin), a six-month injectable heartworm preventive.

The label changes concern use of the product in heartworm-positive dogs and death, "in rare cases."

In accordance with FDA protocol, manufacturer Fort Dodge Animal Health sent letters to all U.S. practitioners in August outlining the label changes. The company explained that a "low number of heartworm positive dogs experienced coughing or cardiopulmonary signs after receiving ProHeart 6," as well as explaining the second change, "death has been reported in approximately 0.0025 percent of the doses sold in veterinary clinics (approximately 2.5 per 100,000 doses). Some of the reports are associated with severe allergic events, while others appear to be multifactorial in nature. Some are linked to factors not associated with product use." The FDA claims that nine of the 240 reported deaths are directly tied to the drug. The others could not be conclusively connected.

Overall, the company says, year-to-date reported adverse reactions are down 19 percent compared to last year.

Advertisement

By law, drug manufacturers must report all adverse reactions brought to their attention to the FDA.

"When this drug was initially marketed, it was believed to be safe for heartworm positive dogs; then we found that dogs were dying that were heartworm positive," says Dr. Victoria Hampshire, the FDA's adverse drug events coordinator.

She urges practitioners not to view Fort Dodge's letter as "junk mail."

"In the hustle and bustle of everyday practice, it's really important that veterinarians know what kind of dogs they're dealing with," Hampshire says. "The take-home message is to do a thorough physical exam before administering this drug."

In a written statement to DVM Newsmagazine, Fort Dodge stands by the safety and efficacy of its product.

"As is typical in the case of a new product after introduction to a wide population base, we have received reports that were not seen in pre-approval clinical studies." The label change, it says, is all part of FDA's post-approval experience. The product debuted in June 2001.

The statement adds, "We have been in regular correspondence with veterinarians regarding field reports. We have initiated adjustments to the label statements in conjunction with the FDA's Center for Veterinary Medicine, as necessary, to reflect that post-approval experience."

Veterinarians with questions about ProHeart 6 can contact a Fort Dodge technical services veterinarian at (800) 477-1365.

FDA's Annual and Cumulative Adverse Drug Experience Reports lists all adverse drug reports. Visit www.fda.gov/cvm-/index/ade/ade_webrpts.pdf for more information.

Related Content:

Regulatory
What you need to know about GFI #256 and the changing landscape of compounding medicine
What you need to know about GFI #256 and the changing landscape of compounding medicine
3 common misconceptions in controlled substance regulations
3 common misconceptions in controlled substance regulations
FDA hosts virtual listening session on regulation of animal food
FDA hosts virtual listening session on regulation of animal food

Advertisement

Latest News

The four-letter word to why you're burning out and feeling unproductive

Merck Manuals recognizes importance of One Health concept

Topical therapy and immunotherapy can save time and frustration with dermatology cases

Texas Tech appoints new faculty member with passion for animal agriculture

View More Latest News
Advertisement